Gilead partners with Global Fund to accelerate lenacapavir HIV prevention access in South Africa

Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

0.00
  • Gilead partnered with South Africa’s government, the Global Fund, PEPFAR to accelerate access to twice-yearly lenacapavir for HIV prevention.
  • Initial supply will be delivered at no profit to Gilead, ahead of broader rollout of generic versions.
  • Royalty-free voluntary licenses with six generic manufacturers target supply across 120 low- and lower-middle-income countries.
  • South Africa launch targets a market with about 7.8 million people living with HIV, with roughly 170,000 new infections annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260605187130) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.